Skip to main content
Growth Hormoneendocrinerecovery

CJC-1295

Also known as: CJC-1295 DAC, DAC:GRF

By the Peptide Dossier Editorial TeamUpdated How we source

CJC-1295 is an investigational GHRH analog whose studied long-acting albumin-binding material raises GH and IGF-1. DAC and non-DAC naming is inconsistent; short hormone studies do not establish muscle, recovery or anti-aging treatment benefits.

Quick Facts

Class:GHRH analog (secretagogue)
Evidence context:Short healthy-adult GH/IGF-1 and pharmacokinetic studies of DAC-related material; clinical wellness outcomes remain unestablished.
Product context:No FDA-approved CJC-1295 product; nominated-but-withdrawn compounding status is not approval.

What is CJC-1295?

CJC-1295 modifies a GHRH backbone to resist breakdown. The original development material binds albumin through its DAC design. Research sellers also use “CJC-1295 without DAC” for modified GRF 1–29, a distinct preparation. The studied long-acting material had an estimated half-life of 5.8–8.1 days; that figure cannot be assigned to an unspecified no-DAC product.

Sources: [1], [6]

How does it work?

GHRH-receptor activation stimulates pituitary GH release and downstream IGF-1. The DAC maleimidopropionyl linker covalently binds albumin and prolongs exposure. Marketed body-composition claims extrapolate from hormonal effects rather than directly demonstrated clinical outcomes.

Teichman and colleagues’ 2006 randomized placebo-controlled studies in healthy adults aged 21–61 found a 2–10-fold mean GH increase lasting at least six days after one injection and a 1.5–3-fold IGF-1 increase for nine to eleven days. Repeated dosing maintained IGF-1 elevation up to 28 days. In a follow-up in men aged 20–40, GH pulses remained, while trough levels rose 7.5-fold and IGF-1 was about 45% higher at one week. Pulse preservation does not mean long-term safety is established.

Sources: [2], [5]

Is it FDA-approved?

No CJC-1295 product is FDA-approved. FDA lists the substance among nominated-but-withdrawn compounding materials rather than on the final 503A bulks list or in Category 1. Removal from Category 2 after withdrawal was not a safety finding or approval. WADA prohibits GHRH analogs and growth-hormone-releasing factors at all times in sport.

Sources: [7]

What does the research show?

The best-characterized human trials are short pharmacology studies, including 28- and 49-day protocols, rather than trials of muscle gain, fat loss, sleep, bone or longevity. The Phase 1 report described sustained dose-dependent hormone rises and short-term tolerability. Related long-acting GHRH research in older adults reported glucose-tolerance impairment, but it should not be mislabeled as a direct CJC-1295 clinical result.

No published randomized human study establishes the common CJC-1295/ipamorelin combination. A physiological rationale involving separate receptors is not proof of clinical synergy, a safe stack or a protective cycling schedule.

Sources: [3], [4]

Identity, safety and research protocol limits

FDA’s December 2024 evaluation separates non-DAC free-base/acetate forms from DAC-related substances. It found no data adequate to assess non-DAC safety/effectiveness; clinical references concerned DAC-related material with unspecified salt forms. It also found insufficient effectiveness evidence for the evaluated subcutaneous substances in GH deficiency.

The studies used weight-based subcutaneous doses and weekly/biweekly research schedules. They do not validate a universal 100-microgram, 0.3–0.5 mg or 2–3 mg regimen, intramuscular substitution, bodybuilding cycle, reconstitution volume or refrigerated shelf life.

FDA separately describes immunogenicity, impurities, increased heart rate and systemic vasodilation. An unpublished HIV-lipodystrophy trial was reportedly stopped after a participant died, based on anecdotal information in the evaluation; causation was not established. Acute GHRH/GHRP-6 synergy in 18 healthy men involved neither CJC-1295 nor ipamorelin.

References and further reading

This reference draws on Superpower’s Peptide Library and the research linked below. Peptide Dossier’s editorial team adapted and integrated the material on .

  1. pubmed.ncbi.nlm.nih.govWhat is CJC-1295?Cited in: What is CJC-1295?
  2. pubmed.ncbi.nlm.nih.govHow does it work?Cited in: How does it work?
  3. 10.1210/jc.2005-1536What does the research show?Cited in: What does the research show?
  4. 10.1530/eje.1.01965What does the research show?Cited in: What does the research show?
  5. pubmed.ncbi.nlm.nih.govHow does it work?Cited in: How does it work?
  6. pubmed.ncbi.nlm.nih.govWhat is CJC-1295?Cited in: What is CJC-1295?
  7. fda.govIs it FDA-approved?Cited in: Is it FDA-approved?
  8. pubmed.ncbi.nlm.nih.govFrequently asked questionsCited in: Frequently asked questions
  9. www.fda.gov — additional reading
  10. pubmed.ncbi.nlm.nih.gov — additional reading

Frequently Asked Questions About CJC-1295

CJC-1295 is a name used inconsistently. The long-acting DAC-related material studied in healthy adults is not interchangeable with a product labeled without DAC.

Short trials demonstrate GH and IGF-I changes. They do not establish a standard amount of muscle gain, fat loss, sleep improvement or an anti-aging benefit.

The cited trials used research-specific, weight-based exposures. They do not establish a universal flat dose, home schedule, mixing recipe or cycle.

FDA identifies increased heart rate, systemic vasodilatory reactions and peptide-quality concerns. A short trial abstract reported no serious reactions; that does not establish years of safety.

The cited human GHRH/GHRP-6 study did not test CJC-1295 or ipamorelin. It does not establish that this combination is the best stack or improves clinical outcomes.

The cited trials establish a hormone response, not a fixed timeline for muscle gain, fat loss or sleep improvement.

Long-term human safety is unknown. Retained GH pulses and short-term tolerability do not establish safe extended use or a protective cycling calendar.

DAC-related and non-DAC substances have different identities. FDA found clinical references concerned DAC-related material; its multi-day pharmacokinetics cannot be assigned to a non-DAC product.

The studied DAC-related material forms an albumin conjugate and has multiday exposure. “No-DAC” modified GRF 1–29 is distinct, and its human half-life is not established by these studies. Their identities and pharmacokinetics are not interchangeable.

No. It is not an approved drug product, and the described nominated-but-withdrawn status does not supply routine 503A eligibility. Tesamorelin has a separate approved HIV-lipodystrophy indication and is not the same product.

A single studied DAC-related exposure maintained IGF-1 elevation for nine to eleven days; one young-men study reported about 45% elevation at a week. These are hormone outcomes, not a timeline for visible physique benefits or no-DAC pharmacokinetics.

Short studies reported generally mild local/systemic effects and no serious reactions, but FDA separately identifies serious increased-heart-rate and systemic-vasodilatory events plus peptide-quality/immune concerns. Long-term safety remains unknown.

No. Research-vendor access is not FDA approval or pharmaceutical-quality oversight, and a prescription alone does not establish eligibility for a withdrawn 503A substance.

No. A withdrawn nomination is not a finding of safety and does not place the substance on the final bulks list or Category 1. FDA continues to describe potential risks.

No. Both act at the GHRH receptor, but CJC-1295 has four substitutions and, with DAC, albumin conjugation. Sermorelin is the native 29-residue fragment; a healthy-men IV study reported a disappearance half-time around four minutes, rather than the studied CJC-DAC multiday half-life.

Sources: [8]

Related Peptides

Continue exploring CJC-1295

Search all related references →

Our library review is ongoing. Read how we evaluate evidence or report a correction.

Disclaimer: This article is for informational and educational purposes only. It is not intended as medical advice. The information presented is based on published research and should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting any peptide protocol. Some peptides discussed may not be approved for human use by the FDA or equivalent regulatory bodies.